We investigated the relationship between iodine-123-metaiodobenzylguanidine ( 123 I-MIBG) findings and myocardial contractile reserve in patients with mild to moderate dilated cardiomyopathy (DCM). BACKGROUND Little is known regarding the relationship between cardiac sympathetic nervous function and myocardial contractile reserve in DCM.
Previous clinical studies have demonstrated the diminished myocardial contractile reserve in response to pacing-induced tachycardia in patients with dilated cardiomyopathy (DCM) (1, 2) . Some studies have shown that myocardial contractile reserve reflects the severity of DCM and is a prognostic determinant in patients with idiopathic DCM (3, 4) . In general, myocardial contractile function is thought to be determined by myocardial intracellular Ca 2ϩ handling, which consists of Ca 2ϩ releasing factors from sarcoplasmic reticulum such as ryanodine receptor-2 and intracellular Ca 2ϩ -regulating factors such as sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA2) and phospholamban (5) (6) (7) (8) . We previously demonstrated the relationship between an abnormal myocardial contractile reserve and a reduced messenger ribonucleic acid (mRNA) expression of SERCA2 in patients with hypertrophic cardiomyopathy (9) . Therefore, it is of interest to assess the relation of myocardial contractile reserve to Ca 2ϩ -handling proteins in DCM. Iodine-123-metaiodobenzylguanidine ( 123 I-MIBG) is a useful imaging tracer that shares similar myocardial uptake, storage, and release mechanisms as norepinephrine (NE) in sympathetic nerve terminals. Measurements of a 123 I-MIBG heart-mediastinum ratio (HMR) and washout rate have enabled more detailed assessment of the function and integrity of myocardial sympathetic innervation. It is well known that myocardial 123 I-MIBG accumulation is reduced in patients with heart failure by enhanced NE spillover from cardiomyocyte (10) . It has been reported that reduced myocardial 123 I-MIBG accumulation is correlated with diminished left ventricular (LV) function in patients with heart failure (11, 12) . However, the relation between cardiac sympathetic function and myocardial contractile reserve in patients with DCM still remains to be established.
Accordingly, in the present study we determined the relationship between cardiac sympathetic function, contractile reserve, and myocardial cellular Ca 2ϩ handling, and investigated whether myocardial 123 I-MIBG scintigraphy could be useful in noninvasively evaluating myocardial contractile reserve in patients with mild to moderate DCM.
MATERIALS AND METHODS
Study population. Twenty-four patients with mild to moderate DCM, who showed sinus rhythm on electrocardiogram, were enrolled in this study. A detailed history was obtained and a physical examination was performed for all patients before inclusion in this study. According to the definition of the World Health Organization/International Society and Federation of Cardiology, DCM is a heart muscle disease of unknown origin with predominant impairment of the systolic function (13) . Criteria for enrollment in this study were normal coronary artery and no evidence of specific cardiomyopathy such as ischemic, valvular, hypertensive, diabetic, alcoholic, inflammatory, or systemic cardiomyopathy. Patients were excluded if they had atrial fibrillation, neuromuscular diseases, or parkinsonism. No patients had received reserpine, tricyclic antidepressant, or other drugs that could interfere with NE kinetics. All patients were hospitalized for examinations and underwent echocardiography, cardiac catheterization, and resting myocardial 123 I-MIBG scintigraphy. Endomyocardial biopsy was performed to analyze real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). Sixteen patients had been treated with angiotensin-converting enzyme inhibitors, thirteen with diuretics, eight with digitalis, six with angiotensin receptor blockades, and three with beta-blockers. All medications were withdrawn at least 72 h before the study. The study protocol was approved by our institutional review committee. Written informed consent was obtained from all patients. 123 I-MIBG imaging. Myocardial 123 I-MIBG scintigraphy was performed after an overnight fast. One hundred fortyeight MBq (4 mCi) of 123 I-MIBG was injected intravenously through the antecubital vein at rest. The planar view was obtained approximately 15 min and 4 h after the tracer injection. A two-head gamma camera (ECAM; Toshiba, Tokyo, Japan) equipped with a low-energy high-resolution collimator was rotated over a 180°arc with an acquisition time of 20 s per image at 4°intervals for each view. Energy discrimination was provided by a 20% window centered at 159 keV. Biventricular cardiac catheterization and echocardiography. All patients underwent biventricular catheterization using brachial approach in fasting state. A 20-gauge catheter was placed in the left brachial artery to measure arterial pressures. A 6-F fluid-filled pigtail catheter with a high-fidelity micromanometer (model SPC-464D; Millar Instruments, Houston, Texas) was advanced into the LV cavity through a 6-F sheath in the right brachial artery to measure LV pressures. A 7-F triple-lumen Swan-Ganz thermodilution catheter (Baxter Healthcare, Deerfield, Illinois) was positioned in the right pulmonary artery through the right brachial vein to measure pulmonary artery wedge pressure (PAWP) and cardiac index (CI). A 6-F bipolar pacing catheter was introduced through the right subclavian vein and positioned in the high right atrium. After baseline data were obtained, right atrial pacing was initiated at 80 beats/min and increased in increments of 10 beats/min up to the maximum value of 140 beats/min.
All patients underwent two-dimensional echocardiography with a Hewlett-Packard ultrasound system (Sonos 2500; Andover, Massachusetts) equipped with a 2.5-to 3.5-MHz transducer to measure wall thickness, cardiac chamber size, and fractional shortening (FS) at rest. 123 I-MIBG analysis. Myocardial 123 I-MIBG uptake was quantified in anterior planar views at 15 min (early image) and 4 h (delayed image) after tracer injection. After regions of interest over the whole heart (H) and over the upper mediastinum (M) were set, an HMR was calculated. In our laboratory, the normal 123 I-MIBG HMR values of the early and delayed images obtained from other age-matched controls (9 male and 1 female, mean age 53 Ϯ 9 years) were 1.9 to 2.8 and 1.8 to 2.7, respectively. Cardiac hemodynamic analysis. Micromanometer pressure signals and standard electrocardiograms were recorded with a multichannel recorder (MR-40, TEAC, Tokyo, Japan) throughout the study. Left ventricular pressure signals were digitized at 3-ms intervals and analyzed with software developed in our laboratory with a 32-bit microcomputer system (PC-9821-ST20; NEC, Tokyo, Japan). Hemodynamic data were analyzed by two independent observers who were unaware of the clinical, echocardiographic, and scintigraphic data. We selected steady-state LV pressure data at baseline and at each pacing rate for analysis, then measured LV end-diastolic pressure (LVEDP), the maximum first derivative of LV pressure (LV dP/dt max ) as an index of contractility, and the pressure half-time (T 1/2 ) to evaluate LV isovolumic relaxation according to Mirsky's method (14) . A biphasic pattern of change, with an initially positive and subsequently negative slope in the force-frequency relation, and a flat pattern of change without initial increasing in the force-frequency relation (e.g., the percent change in LV dP/dt max from the baseline to the maximum value is Ͻ10%) are considered to be worsening changes. Both patterns of changes indicate
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ϭ dilated cardiomyopathy HMR ϭ heart-mediastinum ratio 123 I-MIBG ϭ iodine-123-metaiodobenzylguanidine LV ϭ left ventricular LV dP/dt max ϭ maximum first derivative of left ventricular pressure LVEF ϭ left ventricular ejection fraction mRNA ϭ messenger ribonucleic acid NE ϭ norepinephrine SERCA2 ϭ sarcoplasmic reticulum Ca 2ϩ -ATPase T 1/2 ϭ pressure half-time impairment in myocardial contractile reserve (15) . We defined the critical heart rate (HR) as the HR at which LV dP/dt max reached the maximum value during a progressive increase in HR. Thus, the value beyond which LV dP/dt max declined by 5% was the critical HR for isovolumic contraction (16, 17) . The peak pacing rates were defined as the HR at which either second-degree atrioventricular block or pulsus alternans occurred (17) . After completion of the pacing study, selective coronary angiography, left ventriculography, and endomyocardial biopsy were performed. Left ventricular end-diastolic volume, LV end-systolic volume, and stroke volume were measured by contrast-enhanced left ventriculography. Left ventricular end-diastolic volume index (LVEDVI), LV end-systolic volume index (LVESVI), stroke volume index (SI), and LV ejection fraction (LVEF) were calculated according to the Sandler and Dodge method (18) . In right cardiac catheterization, PAWP and CI were measured using a Swan-Ganz thermodilution catheter. Several biopsy specimens were obtained from the left side of the interventricular septum. Biopsy specimens for mRNA analysis were frozen immediately in liquid nitrogen and stored at Ϫ80°C until use.
Echocardiographic data were analyzed by two independent observers who were unaware of the clinical, hemodynamic, and scintigraphic data. In two-dimensional echocardiography, the LV end-diastolic dimension (LVEDD), LV end-systolic dimension (LVESD), interventricular septal thickness (IVST), posterior wall thickness (PWT), and FS were measured on the M-mode of the long-axis image according to standard criteria (19) . Measurement of neurohumoral factors. The blood sample was immediately placed on ice and centrifuged at 4°C. The plasma NE levels were measured using highperformance liquid chromatography. The plasma brain natriuretic peptide (BNP) levels were measured with a specific radioimmunoassay for human BNP using a commercially available kit. RT-PCR analysis. The total ribonucleic acid was isolated from 1 to 2.5 mg of the frozen samples of LV biopsy specimens and subjected to real-time quantitative RT-PCR analysis as previously described (20) . The mRNA expressions of intracellular Ca 2ϩ -regulatory proteins, including SERCA2, ryanodine receptor-2, phospholamban, calsequestrin, and Na ϩ /Ca 2ϩ exchanger, were analyzed by a fluorogenic 5=-nuclease PCR assay using an ABI PRISM 7700 sequence detector (Perkin-Elmer, Wellesley, Massachusetts). All PCR assays were performed in triplicate. TaqMan glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control reagents (Perkin-Elmer) were used for the detection of human GAPDH transcript as an internal standard. Statistical analysis. Data were expressed as mean values Ϯ SD. An unpaired Student t test was performed to determine differences between mean values for continuous variables when appropriate. Neurohumoral factors (BNP, NE) were not normally distributed. Therefore, the nonparametric Mann-Whitney U test was used to assess differences. Correlations between scintigraphic and hemodynamic parameters were performed by linear regression analysis. A multiple linear regression analysis was performed using the percentage change in LV dP/dt max as dependent parameter. Age, LV wall thickness, LV volume index, LVEF, neurohumoral factors, and delayed 123 I-MIBG HMR were used as independent parameters. The partial regression coefficient (␤) was calculated to assess significant independent parameters. A threshold value of a delayed MIBG HMR for detecting an abnormal contractile response was defined by receiver-operating characteristic analysis. A p value Ͻ0.05 was considered statistically significant.
RESULTS
Patient demographics. The demographics of the patients enrolled in this study are summarized in Table 1 . The mean age of the 24 patients (20 men, 4 women) was 53 Ϯ 10 years. Nineteen patients were classified as New York Heart Association (NYHA) functional class I, and five patients as NYHA class II. The mean cardiothoracic ratio was 52 Ϯ 7%. The LVEDD and LVESD derived from echocardiography were 59 Ϯ 10 mm and 47 Ϯ 9 mm, respectively, and the LVEDVI and LVESVI derived from contrast ventriculography were 90 Ϯ 55 ml/m 2 and 55 Ϯ 25 ml/m 2 , respectively, suggesting LV dilatation. The IVST and PWT were 8.3 Ϯ 1.3 mm and 8.3 Ϯ 1.3 mm, respectively, suggesting a tendency to wall thinning. The LVEF and FS were reduced, with mean values of 41 Ϯ 7.0% and 21 Ϯ No adverse complications were observed in the hemodynamic study. A significant correlation was observed between the delayed 123 I-MIBG HMR and the percentage change in LV dP/dt max from the baseline to the peak or critical HR (r ϭ 0.64; p Ͻ 0.001) (Fig. 1) . A positive linear correlation was observed between the delayed 123 I-MIBG HMR and the percentage shortening in T 1/2 from the baseline to the peak HR, but it did not reach statistical significance (r ϭ 0.35; p ϭ 0.08). No significant correlation was observed between the delayed HMR and other hemodynamic parameters (LV dimensions, LVEF, LV volume indexes, LVEDP, PAWP, or CI) derived from echocardiography or biventricular catheterization. No significant correlation was observed between the early 123 I-MIBG HMR and any hemodynamic parameters. A multiple regression analysis revealed that the delayed 123 I-MIBG HMR was a significant independent parameter for the percentage change in LV dP/dt max (␤ ϭ 0.47; p ϭ 0.03).
Comparison of patients with and without worsening changes in LV dP/dt max . When we divided the DCM patients based on the rate-dependent changes in LV dP/ dt max , the delayed 123 I-MIBG HMR was significantly lower in patients with worsening changes than in those showing non-worsening changes (p Ͻ 0.005) ( Table 2 ). In the echocardiographic study, the LVEDD and LVESD were significantly greater in patients showing worsening changes than in those showing non-worsening changes in LV dP/dt max (p Ͻ 0.05) ( Table 2 ). In the hemodynamic study, no significant difference was observed in the percentage change in HR during the pacing study in the two groups. No significant difference was observed in the baseline systolic blood pressure, the baseline diastolic blood pressure, the peak systolic blood pressure, or the peak diastolic blood pressure in the two groups ( Table 2 ). The LVEDVI and LVESVI were also significantly greater in patients showing worsening changes than in those showing non-worsening changes (p Ͻ 0.05, respectively) ( Table 2 ). The peak T 1/2 was significantly less prolonged in patients with worsening changes than in those showing non-worsening changes (p Ͻ 0.05) ( Table 2 ). The calsequestrin mRNA levels were significantly lower in patients with worsening changes than in those showing non-worsening changes (p Ͻ 0.05) ( Table 2) . Comparison of patients with and without a low HMR. At the threshold value of a delayed 123 I-MIBG HMR of Յ1.8, the sensitivity, specificity, and accuracy for detecting patients showing worsening changes in LV dP/dt max were 81.8%, 84.6%, and 83.3%, respectively, using receiveroperating characteristic analysis. According to the quantitative 123 I-MIBG findings, we divided the DCM patients into two groups as follows: 10 patients with a low delayed HMR (delayed HMR Յ1.8) and 14 without it (delayed HMR Ͼ1.8).
The maximum LV dP/dt max during pacing was significantly more reduced in patients with a low HMR than in those without it (1,337 Ϯ 275 mm Hg/s vs. 1,705 Ϯ 349 mm Hg/s; p ϭ 0.011). The percentage change in LV dP/dt max from the baseline to the peak or critical HR was less in patients with a low HMR than in those without it (11 Ϯ 5.4% vs. 20 Ϯ 8.3%; p ϭ 0.0079). The worsening change in LV dP/dt max was more frequently observed in patients with a low HMR than in those without it (8 of 10 patients [80%] vs. 2 of 14 patients [14%]; p ϭ 0.0008). The percentage shortening in T 1/2 from the baseline to the peak HR was significantly less in patients with a low HMR than in those without it (Ϫ21 Ϯ 7.2% vs. Ϫ30 Ϯ 5.8%; p ϭ 0.047). The plasma NE levels were higher in patients with a low HMR than in those without it (671 Ϯ 266 pg/ml vs. 460 Ϯ 173 pg/ml; p ϭ 0.0091). The SERCA2 mRNA levels were significantly lower in patients with a low HMR than in those without it (SERCA2/GAPDH ratio: 0.335 Ϯ 0.053 vs. 0.453 Ϯ 0.053; p Ͻ 0.01).
Myocardial 123 I-MIBG scintigraphy and the changes in LV dP/dt max of two typical cases are presented in Figures 2  and 3 .
DISCUSSION
In this study, a significant correlation was observed between the change in the acceleration of contractility (percentage change in LV dP/dt max from the baseline to the peak or critical HR) during atrial pacing and the quantitative myocardial 123 I-MIBG uptake (delayed 123 I-MIBG HMR). Patients with an inability to increase LV dP/dt max exhibited lower 123 I-MIBG HMR than those without it. In addition, the SERCA2 mRNA levels were lower in patients with impaired sympathetic nervous function than in those with relatively preserved function. These results suggest that abnormal 123 I-MIBG findings may be related to the im- Figure 1 . Relationship between the delayed iodine-123-metaiodobenzylguanidine heart-mediastinum ratio (HMR) and the percentage change in LV dP/dt max from the baseline to the peak or critical heart rate. LV dP/dt max ϭ maximum first derivative of left ventricular pressure. (5) (6) (7) (8) . We previously demonstrated that an abnormal contractile reserve is caused by a reduced mRNA expression of SERCA2 in patients with hypertrophic cardiomyopathy (9) . In this study, patients with impaired contractile reserve Data are expressed as mean values Ϯ SD. BNP ϭ brain natriuretic peptide; CQ ϭ calsequestrin; DBP ϭ diastolic blood pressure; GAPDH ϭ glyceraldehyde-3-phosphate dehydrogenase; HR ϭ heart rate; HMR ϭ heart to mediastinum ratio; LV dP/dt max ϭ maximum first derivative of left ventricular pressure; NE ϭ norepinephrine; PAWP ϭ pulmonary artery wedge pressure; PLB ϭ phospholamban; RyR ϭ ryanodine receptor-2; SBP ϭ systolic blood pressure; SERCA2 ϭ sarcoplasmic reticulum Ca 2ϩ -ATPase; T 1/2 ϭ pressure half-time; % ϭ percentage change in parameters from the baseline to the peak or critical heart rate; ⌬ ϭ absolute change in parameters from the baseline to the peak or critical heart rate; other abbreviations as in Table 1. showed reduced mRNA expression of calsequestrin, and no significant difference in mRNA abundance for SERCA2 was observed between the subgroups. However, SERCA2/ GAPDH ratio was significantly lower in DCM patients with a low HMR than in those without it, probably indicating that reduced expression of SERCA2 is associated with impaired cardiac sympathetic activity. Previous studies have mentioned that expression of SERCA2 increases after beta-blocker treatment, suggesting a causal link between beta-blocker therapy and expression of Ca 2ϩ -regulatory proteins in patients with mild to moderate heart failure (21, 22) . Our results may support the demonstrations of these previous studies. Abnormal quantitative 123 I-MIBG findings may reflect the abnormal myocardial contractile reserve, which is associated with abnormal Ca 2ϩ handlings. We found that some DCM patients show worsening changes in LV dP/dt max . Previous clinical studies have demonstrated diminished myocardial contractile reserve during pacing-induced tachycardia in patients with DCM (1,2). Some studies have also indicated that potentiation of the force of contraction is attenuated or absent in the failing myocardium (15, 23, 24) . These results are in accord with our results. In DCM patients with worsening changes in LV dP/dt max , the delayed 123 I-MIBG HMR was significantly 
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The relationship between heart rate (HR) and LV dP/dt max of this patient is shown. The baseline LV dP/dt max and maximum LV dP/dt max are 1,107 mm Hg/s and 1,284 mm Hg/s, respectively. The percentage change in LV dP/dt max from the baseline to the critical HR is 10%. A biphasic pattern of change in LV dP/dt max is observed. bpm ϭ beats per minute; other abbreviations as in Figure 1 . The relationship between HR and LV dP/dt max of this patient is shown. The baseline LV dP/dt max and maximum LV dP/dt max are 1,224 mm Hg/s and 1,509 mm Hg/s, respectively. The percentage change in LV dP/dt max from the baseline to the peak HR is 27%. A progressively increasing pattern of change in LV dP/dt max is observed. Abbreviations as in Figures 1 and 2 .
